Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Ibrutinib-venetoclax produces high MRD-negative rates in CLL/SLL

Key clinical point: Ibrutinib-venetoclax appears to be an effective first-line therapy for CLL/SLL.

Major finding: 75% of patients were MRD-negative in peripheral blood, and 68% in bone marrow in an intention-to-treat analysis.

Study details: Open-label portion of a phase 2 trial of 164 patients with untreated CLL/SLL.

Disclosures: Dr. Siddiqi disclosed research funding and speakers bureau activity for Pharmacyclics, which sponsored the study, and others, as well as consulting/advising for several companies. Dr. Coombs disclosed consulting for AbbVie.


Siddiqi T et al. EHA25. Abstract S158.